Cargando…
Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
Sodium–glucose cotransporter 2 inhibitors (SGLT2is) are glucose-lowering agents whose positive impact on cardiovascular risk has been described extensively. Not only do they influence lipid profile, blood pressure, atherosclerosis risk, hemoglobin level, and insulin resistance, but they also reduce...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380892/ https://www.ncbi.nlm.nih.gov/pubmed/37504524 http://dx.doi.org/10.3390/jcdd10070268 |
_version_ | 1785080307551043584 |
---|---|
author | Kochanowska, Anna Rusztyn, Przemysław Szczerkowska, Karolina Surma, Stanisław Gąsecka, Aleksandra Jaguszewski, Miłosz J. Szarpak, Łukasz Filipiak, Krzysztof J. |
author_facet | Kochanowska, Anna Rusztyn, Przemysław Szczerkowska, Karolina Surma, Stanisław Gąsecka, Aleksandra Jaguszewski, Miłosz J. Szarpak, Łukasz Filipiak, Krzysztof J. |
author_sort | Kochanowska, Anna |
collection | PubMed |
description | Sodium–glucose cotransporter 2 inhibitors (SGLT2is) are glucose-lowering agents whose positive impact on cardiovascular risk has been described extensively. Not only do they influence lipid profile, blood pressure, atherosclerosis risk, hemoglobin level, and insulin resistance, but they also reduce cardiovascular events, all-cause mortality, and hospitalization rates. Some of these effects may be due to their impact on serum uric acid (SUA) concentration. Findings from nine meta-analyses showed that, indeed, SGLT2is significantly reduce SUA. The data on the drug- and dose-dependency of this effect were inconclusive. Several factors alternating the beneficial effects of SGLT2is on SUA, such as glycated hemoglobin concentration (HbA1c), presence of diabetes, and baseline SUA level, were described. Even though there is a consensus that the lowering of SUA by SGLT2is might be due to the increased urinary excretion rate of uric acid (UEUA) rather than its altered metabolism, the exact mechanism remains unknown. The influence of SGLT2is on SUA may not only be used in gout treatment but may also be of huge importance in explaining the observed pleiotropic effects of SGLT2is. |
format | Online Article Text |
id | pubmed-10380892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103808922023-07-29 Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action Kochanowska, Anna Rusztyn, Przemysław Szczerkowska, Karolina Surma, Stanisław Gąsecka, Aleksandra Jaguszewski, Miłosz J. Szarpak, Łukasz Filipiak, Krzysztof J. J Cardiovasc Dev Dis Review Sodium–glucose cotransporter 2 inhibitors (SGLT2is) are glucose-lowering agents whose positive impact on cardiovascular risk has been described extensively. Not only do they influence lipid profile, blood pressure, atherosclerosis risk, hemoglobin level, and insulin resistance, but they also reduce cardiovascular events, all-cause mortality, and hospitalization rates. Some of these effects may be due to their impact on serum uric acid (SUA) concentration. Findings from nine meta-analyses showed that, indeed, SGLT2is significantly reduce SUA. The data on the drug- and dose-dependency of this effect were inconclusive. Several factors alternating the beneficial effects of SGLT2is on SUA, such as glycated hemoglobin concentration (HbA1c), presence of diabetes, and baseline SUA level, were described. Even though there is a consensus that the lowering of SUA by SGLT2is might be due to the increased urinary excretion rate of uric acid (UEUA) rather than its altered metabolism, the exact mechanism remains unknown. The influence of SGLT2is on SUA may not only be used in gout treatment but may also be of huge importance in explaining the observed pleiotropic effects of SGLT2is. MDPI 2023-06-22 /pmc/articles/PMC10380892/ /pubmed/37504524 http://dx.doi.org/10.3390/jcdd10070268 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kochanowska, Anna Rusztyn, Przemysław Szczerkowska, Karolina Surma, Stanisław Gąsecka, Aleksandra Jaguszewski, Miłosz J. Szarpak, Łukasz Filipiak, Krzysztof J. Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action |
title | Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action |
title_full | Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action |
title_fullStr | Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action |
title_full_unstemmed | Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action |
title_short | Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action |
title_sort | sodium–glucose cotransporter 2 inhibitors to decrease the uric acid concentration—a novel mechanism of action |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380892/ https://www.ncbi.nlm.nih.gov/pubmed/37504524 http://dx.doi.org/10.3390/jcdd10070268 |
work_keys_str_mv | AT kochanowskaanna sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction AT rusztynprzemysław sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction AT szczerkowskakarolina sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction AT surmastanisław sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction AT gaseckaaleksandra sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction AT jaguszewskimiłoszj sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction AT szarpakłukasz sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction AT filipiakkrzysztofj sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction |